Aprogen’s ‘Remicade’ biosimilar break into KRW 1 trillion Japanese market

Published: 2017-09-29 13:49:57

Updated: 2017-09-29 13:49:57

A ‘Remicade’ biosimilar developed by Aprogen has made a stepping stone to enter the KRW 1 trillion Japanese market.

Aprogen(CEO Jae-Seop Kim), a biosimilar company, announced the company acquired approval of its Remicade biosimilar(Japanese code name: NI-071) developed by the company from the Ministry of Health, Labour and Welfare on the 27^th.

It project name was dually registered under names...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.